Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre

Background Several unanswered questions surround the management of retroperitoneal sarcoma (RPS). Guidelines recommend treatment by a multidisciplinary team at a specialized referral centre. The objective of this study was to describe the management of RPS at an Australian specialist sarcoma centre,...

Full description

Saved in:
Bibliographic Details
Published in:ANZ journal of surgery 2018-11, Vol.88 (11), p.1151-1157
Main Authors: Snow, Hayden A., Hitchen, Tatiana X., Head, Jessica, Herschtal, Alan, Bae, Susie, Chander, Sarat, Chu, Julie, Hendry, Shona, Ngan, Samuel Y., Desai, Jayesh, Choong, Peter F. M., Henderson, Michael, Gyorki, David E.
Format: Article
Language:English
Subjects:
Biopsy
Failure analysis
Gastric cancer
International standards
leiomyosarcoma
liposarcoma
Management
Metastases
Patients
Radiation therapy
recurrence
Sarcoma
Surgery
Survival
tertiary healthcare
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Several unanswered questions surround the management of retroperitoneal sarcoma (RPS). Guidelines recommend treatment by a multidisciplinary team at a specialized referral centre. The objective of this study was to describe the management of RPS at an Australian specialist sarcoma centre, comparing outcomes to international standards and analysing for predictors of local failure. Methods A retrospective review of a prospectively maintained database was performed on patients with RPS treated between 2008 and 2016. A 5‐year outcome analyses focussed on patients undergoing curative‐intent surgery for primary, non‐metastatic RPS. Results Eighty‐eight patients underwent surgery for primary RPS. Five‐year overall survival was 66%, 5‐year freedom from local recurrence was 65% and 5‐year freedom from distant metastasis was 71%. Overall survival was associated with tumour grade (hazard ratio (HR) 6.1, P 
ISSN:1445-1433
1445-2197
DOI:10.1111/ans.14842